Navigation Links
Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology

PASADENA, Calif., July 22 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), Landlord of Choice to the Life Science Industry(R), announced today that an affiliate has entered into a long-term lease with Eli Lilly and Company as the anchor tenant at the Alexandria Center for Science and Technology at East River Science Park ("the Alexandria Center"). Lilly has leased approximately 91,000 rentable square feet, as well as an additional approximately 9,000 rentable square feet of core services space, at the Alexandria Center, which will become the new research headquarters for ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to be New York City's life science collaboration and translational research epicenter. Occupancy is expected in approximately June 2010.

To mark this profound milestone in the continued development of Alexandria's New York City life science cluster, Mayor Michael R. Bloomberg held a press conference today at the Alexandria Center for Science and Technology at East River Science Park, along with New York City Council Speaker Christine C. Quinn, Empire State Development Corporation Chairman and CEO-designate Dennis Mullen, Dr. John C. Lechleiter, Chairman, President and Chief Executive Officer of Eli Lilly and Company, Dr. Larry Witte, Senior Vice President of Research of ImClone Systems and Joel S. Marcus, Chairman, President and Chief Executive Officer of Alexandria Real Estate Equities, Inc., as well as many dignitaries.

ImClone Systems is a leader in the development and commercialization of novel therapeutic products in the field of oncology, such as ERBITUX((R)) (cetuximab) and a broad spectrum of innovative product candidates with potential application in multiple tumor types. Committed to building an oncology powerhouse, Eli Lilly and Company acquired ImClone Systems in November 2008 as a complement to its internal cancer research unit, Lilly Oncology. Locating translational research and development at the Alexandria Center provides ImClone Systems and Lilly Oncology with a unique and highly collaborative platform from which to access renowned medical and research institutions in New York City. Alexandria's New York City presence will leverage the Company's proprietary clustering model to recruit a broad and diverse spectrum of life science entities.

"New York City has always been at the forefront of scientific innovation, but the City has never fully capitalized on its assets to create a thriving commercial bioscience industry and the jobs that come with it," said Mayor Bloomberg. "We joined with Alexandria Real Estate Equities to create the East River Science Park to provide today's bioscience companies with the state-of-the-art commercial lab space they need to locate and expand. Lilly's decision to become its anchor tenant is evidence that our work is paying off. It also serves as a major boost to our efforts to diversify New York City's economy. In recent months, we have announced initiatives to promote entrepreneurship, develop green jobs, support nonprofits, grow the media industry and add industrial jobs, and today's announcement affirms our belief that bioscience is another industry in which the City can and will succeed."

"Alexandria has had a prior relationship with Lilly in one of its primary life science cluster markets and has worked cooperatively on a number of strategic initiatives. Lilly is the first top-tier biopharmaceutical company to base translational research and development operations in New York City," said Joel S. Marcus, Chairman, President and Chief Executive Officer of Alexandria Real Estate Equities, Inc. "Alexandria has now delivered on its strategy to take the positive attributes of New York City and couple them with its world-class life science cluster capabilities to provide the best technical environments in which to conduct and foster cutting edge collaboration among life science entities to produce tomorrow's cost effective medicines that improve the human condition."

About the Alexandria Center for Science and Technology at East River Science Park

The Alexandria Center is poised to become on of the world's leading centers for life science clustering -- a science park in the heart of New York City. The Alexandria Center will ultimately consist of an approximately 1.1 million rentable square foot campus of first-class technical space uniquely designed with Alexandria's novel proprietary products to accommodate and foster collaboration among a broad spectrum of life science entities. The campus will include a state-of-the-art digital conference center, as well as space for clinical and translational research and development. There will also be a notable restaurant, cafe, fitness center and a one acre landscaped science park, with stunning East River views. Located in Manhattan's East Side life science/medical corridor, the science park will capitalize on its proximity to the City's academic medical research institutions and major hospitals. New York City combines the preeminent location of the Alexandria Center with science, capital and talent - the critical components of a successful cluster market. World-class life science entities are attracted to Alexandria's world-renowned scientific research environments located in the leading life science cluster markets world-wide, unique sustainable operations and unique proprietary services.

About Alexandria Real Estate Equities, Inc.

Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry((R)), is the largest owner and preeminent first-in-class real estate investment trust focused principally on science-driven cluster formation. Alexandria is the leading provider of high-quality environmentally sustainable real estate, technical infrastructure and services to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biopharmaceutical, medical device, product, service, and translational entities, as well as government agencies. Alexandria's operating platform is based on the principle of "clustering", with assets and operations located in key life science markets. At March 31, 2009, the Company's asset base approximated 12.8 million rentable square feet consisting of 156 properties approximating 11.7 million rentable square feet (including spaces undergoing active redevelopment) and properties undergoing ground-up development approximating an additional 1.1 million rentable square feet.

This press release contains forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in our Annual Report on Form 10-K and our other periodic reports filed with the Securities and Exchange Commission.

SOURCE Alexandria Real Estate Equities, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock
2. Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
3. Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results
4. Miami Beach Real Estate Attorney Opens Miami Real Estate Brokerage for International Luxury Miami Beach Condo Buyers From Distressed Sellers
5. Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
6. GSI Group Inc. to Restate Financial Results for 2006
7. Miami Beach Real Estate Attorney Announces Services to Assist Chinese and other International Real Estate Investors Purchase Discount Florida Homes
8. BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors
9. Norton & Associates Inc. Adds $3bnUSD Commercial Real Estate Investment P & L Management Holding Group; US Property Portfolio Inc.
10. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
11. Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates
Post Your Comments:
(Date:10/12/2015)... 12, 2015  Rebiotix Inc. today announced that ... its lead Microbiota Restoration Therapy (MRT) RBX2660 as ... Clostridium difficile (C diff) infection, a ... 29,000 deaths in the U.S. annually. 1 ... was founded to revolutionize the treatment of debilitating ...
(Date:10/12/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... developing and commercializing novel treatments in oncology, endocrinology and ... Turpin , the Company,s former Senior Vice President, Chief ... Quebec City office.  ... Officer of the Company commented, "After a comprehensive review, ...
(Date:10/12/2015)... 12, 2015 ... for enriched online experience --> ... print version for enriched online experience --> ... media alternative to print version for enriched online experience ... scientific, technical and medical information products and services, announced ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a specialty biopharmaceutical company focused ... safely and chronically be administered as an eye drop, announced today it has been ... Clinic and taking place October 25th to October 28th at The Cleveland Clinic, Cleveland, ...
Breaking Biology Technology:
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/26/2015)... , Sept. 26th, 2015  Results of a ... be unveiled today at the Stanford Medicine X ... Using iPad Dashboards, Connected Health Devices and Pharmacogenomics", ... Pharmacy 3.0, will explain how senior patients equipped ... to their pharmacist via the TactioRPM remote patient ...
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... quite delivered upon previous expectations of revenues, consumer adoption ... breakthrough year in which wearables begin to achieve that ... of the main reasons is the entrance of Apple ... the SmartWatches market, but the overall size of the ...
Breaking Biology News(10 mins):